Table 1: Mortality studies in psoriatic arthritis.

StudyYearCountryno. of patientsMale, no. [%]Follow-up periodSMR (95% CI)RemarksMajor causes of death

Roberts et al. [11]1976UK16818 deaths occurred9 deaths due to CVD
Coulton et al. [13]1989UK4016 (40)8 yearsNo deaths occurred
Wong et al. [8]1997Canada428234 (54.7)1978 –1993Overall: 1.62 (1.21–2.12)
Male: 1.65 (1.09, 2.04)
Female: 1.59 (1.04, 2.33)
CVD (36.2%), respiratory disease (21.3%)
Shbeeb et al. [10]2000US6632 (48.5)1982–1991Similar survival to the general population
McHugh et al. [3]2003UK8738 (57.6)Median: 65 months9 deaths occurred5 deaths due to CVD
Alamanos et al. [16]2003North-west Greece221108 (48.9)1982–20014 deaths occurred2 deaths due to CVD
Ali et al. [15]2007Canada680385 (56.6)1978–2004Overall: 1.36 (1.12–1.64)
Male: 1.25 (0.95, 1.65)
Female: 1.47 (1.13, 1.91)
Malignancy (23.6%), CVD (24.5%), respiratory diseases (10.4%)
Wilson et al. [9]2009US14790 (61)1970–19990.91 (0.58, 1.37)
Buckley et al. [14]2010UK453232 (51.2)1985–2007Overall: 0.82 (0.58–1.13)
Male: 0.68 (0.39, 1.10)
Female: 0.97 (0.60, 1.48)
CVD (38%), respiratory disease (27%), malignancy (14%)
Ahlehoff et al. [17]2010Denmark6071997–2006RR for all-cause mortality*: 1.74 (1.32–2.30);
RR for cardiovascular death: 1.84 (1.11–3.06)
Mok et al. [12]2011Hong Kong778424 (54)1999–2008Overall: 2.50 (1.81–3.19)
Male: 2.27 (1.44, 3.10)
Female: 2.76 (1.61, 3.91)
Infection (33%), malignancy (20%), CVD (20%)

SMR: standardized mortality ratio; CI: confidence interval; UK: United Kingdom; CVD: cardiovascular disease; US: United States; RR: relative risk.
*Rate ratio (95% confidence interval) compared with 4,003,265 controls, adjusted for age, calendar year, concomitant medication, comorbidity, socio-economic data and gender.